Myovant Sciences Ltd (NASDAQ:MYOV)‘s stock had its “buy” rating reiterated by analysts at Cowen and Company in a report released on Tuesday.

The analysts wrote, “Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of.””

A number of other equities analysts have also weighed in on the stock. Evercore ISI started coverage on shares of Myovant Sciences in a research report on Wednesday, August 16th. They issued an “outperform” rating for the company. JMP Securities reissued an “outperform” rating and issued a $25.00 price objective (up previously from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 16th. Finally, Robert W. Baird reissued a “buy” rating and issued a $20.00 price objective on shares of Myovant Sciences in a research report on Friday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Myovant Sciences has a consensus rating of “Buy” and a consensus price target of $20.00.

Myovant Sciences (MYOV) traded down $0.69 during trading hours on Tuesday, hitting $13.43. 80,410 shares of the stock were exchanged, compared to its average volume of 35,778. Myovant Sciences has a twelve month low of $9.92 and a twelve month high of $18.85.

TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/14/myovant-sciences-ltd-myov-rating-reiterated-by-cowen-and-company.html.

A number of hedge funds have recently modified their holdings of MYOV. Wells Fargo & Company MN increased its position in Myovant Sciences by 331.9% during the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after purchasing an additional 12,700 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Myovant Sciences by 36.3% during the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock worth $279,000 after buying an additional 6,330 shares during the period. JPMorgan Chase & Co. grew its stake in Myovant Sciences by 30.6% during the first quarter. JPMorgan Chase & Co. now owns 83,070 shares of the company’s stock worth $975,000 after buying an additional 19,474 shares during the period. Quantitative Systematic Strategies LLC purchased a new stake in Myovant Sciences during the second quarter worth approximately $165,000. Finally, LMR Partners LLP purchased a new stake in Myovant Sciences during the second quarter worth approximately $320,000.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.